Unither To Acquire UCB New York Plant - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Unither To Acquire UCB New York Plant


Unither Pharmaceuticals, a sterile unit-dose manufacturer, will acquire an UCB pharmaceutical plant in Rochester, NY. The plant employs 250 people and mainly manufacturers liquid pharmaceutical products. This acquisition is a part of Unither's strategy to become a pharmaceutical global player and particularly in blow/fill/seal (BFS) technology. Under the agreement, Unither will continue manufacturing UCB products, and all Rochester's employees will be offered the opportunity to work for Unither. While manufacturing UCB products, Unither intends to install BFS and stick-pack technologies in the Rochester plant to provide its clients or US prospects with locally made products.The transaction is expected to be completed in the fourth quarter of this year, according to a Unither press release.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here